Nurix highlights 2025 and 2026 goals at J.P. Morgan

Nurix Therapeutics, Inc. filed a current report to share that it is presenting at the 44th Annual J.P.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. filed a current report to share that it is presenting at the 44th Annual J.P. Morgan Healthcare Conference. On January 12, 2026, the company is providing an overview of its 2025 performance and outlining major goals for 2026 at the event. The associated investor presentation is included as Exhibit 99.1, and a related press release is included as Exhibit 99.2.

The company notes that this conference information is being furnished under Regulation FD and is not deemed filed for liability purposes under the Securities Exchange Act. The filing is primarily informational and centers on disclosure of the materials used at the conference and the accompanying press release.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nurix Therapeutics (NRIX) disclose in this Form 8-K?

Nurix Therapeutics, Inc. disclosed that it is presenting an overview of its 2025 performance and major 2026 goals at the 44th Annual J.P. Morgan Healthcare Conference, and it furnished the related presentation (Exhibit 99.1) and press release (Exhibit 99.2).

What exhibits are included with Nurix Therapeutics’ (NRIX) conference 8-K?

The filing includes Exhibit 99.1, a Nurix Therapeutics, Inc. presentation dated January 12, 2026, Exhibit 99.2, a press release dated January 12, 2026, and Exhibit 104, the cover page interactive data file.

Is the J.P. Morgan Healthcare Conference information considered filed for liability purposes?

No. Nurix states that the information in Item 7.01, including Exhibits 99.1 and 99.2, is being furnished under Regulation FD and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to that section’s liability, except if specifically incorporated by reference in another filing.

What topics does Nurix plan to cover at the J.P. Morgan Healthcare Conference?

Nurix indicates it will present an overview of its 2025 performance and its major goals for 2026 at the 44th Annual J.P. Morgan Healthcare Conference.

When are Nurix’s presentation and press release dated in this 8-K?

Both the Nurix Therapeutics, Inc. presentation (Exhibit 99.1) and the press release (Exhibit 99.2) are dated January 12, 2026.

Does this Nurix (NRIX) 8-K announce any major transaction or financial results?

The 8-K focuses on furnishing material for the J.P. Morgan Healthcare Conference and does not itself describe specific transactions or detailed financial results; those details, if any, would be in the attached presentation and press release.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 08:34 AM Learn about SEC filing dates

0001549595false01/12/20261600 Sierra Point ParkwayBrisbaneCalifornia00015495952026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 12, 2026

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1600 Sierra Point Parkway, Brisbane, California						94005
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

1700 Owens Street, Suite 205, San Francisco, California

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01    Regulation FD Disclosure.

As previously announced, on January 12, 2026, Nurix Therapeutics, Inc. (the “Company”) will present an overview of the Company’s performance in 2025 and its major goals for 2026 at the 44th Annual J.P. Morgan Healthcare Conference (the “JPM Conference”). A copy of the Company’s presentation materials for the JPM Conference is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Also on January 12, 2026, the Company issued the press release attached as Exhibit 99.2 hereto, which is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:

Exhibit No.						Exhibit Title or Description
99.1						Nurix Therapeutics, Inc. Presentation dated January 12, 2026
99.2						Nurix Therapeutics, Inc. Press Release dated January 12, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: January 12, 2026			By:			/s/ Christine Ring
						Christine Ring, Ph.D., J.D.
						Chief Legal Officer

3